Life Sciences Regulatory & Compliance | McDermott Lawyers

Life Sciences Regulatory & Compliance

Overview


Chambers USA 2021

Experienced Counsel to Guide You Through Industry Growth

Whether you’re a life sciences industry giant or a startup, changes to cybersecurity, pharmaceuticals, medical devices, patient rights and transformative ventures present great opportunities for industry growth, but also new—and sometimes daunting—challenges for your organization. Intense financial penalties, negative rulings and individual accountability are only a few of the risks life sciences companies face if they do not understand and remain compliant with these ever-changing regulations.

McDermott’s global team of regulatory lawyers work with you to create and implement practical plans to anticipate and mitigate potential risks; respond to inquiries by state, national and international agencies; and, if necessary, pursue resolution of disputes in court and before administrative and other tribunals in a way that least disrupts your business.

Show More

Results


Antitrust

  • Amgen in securing antitrust clearance for its $10.4 billion acquisition of Onyx Pharmaceuticals, a global biopharmaceutical company engaged in the development and commercialization of therapies for cancer patients, in Amgen’s largest deal to date
  • Amgen in securing antitrust clearance for its $315 million acquisition of KAI Pharmaceuticals
  • Amgen in all aspects of one of the largest biotechnology cases to go to trial, in which Hoffman La Roche sought to break the six Lin patents that had secured Amgen’s monopoly in the United States

Show More

People


We create and implement practical plans to anticipate and mitigate potential risks and clear your path to success.